Immune Modulation Stack
Thymic function restoration with gut and inflammatory support.
Thymosin Alpha-1 is the primary thymic peptide for immune T-cell maturation and has been clinically used in hepatitis B/C and cancer adjunct protocols. Combined with KPV and Larazotide for gut barrier integrity, this stack addresses immune function from three angles.
What's in this stack
Research Protocol
- Thymosin Alpha-1: 1.5 mg subcutaneous twice weekly
- KPV: 500 mcg oral daily
- BPC-157: 250 mcg twice daily
Ready to start your Immune Modulation Stack research?
Each compound ships COA-verified, >98% purity, cold-packed for stability.
Frequently Asked Questions
What is KPV and how does it modulate inflammation?
KPV is a tripeptide (Lys-Pro-Val) derived from the C-terminal of alpha-MSH. It inhibits NF-κB signalling and pro-inflammatory cytokine production (IL-1β, IL-6, TNF-α) and has been studied in gut inflammatory models including IBD and colitis.
How does Thymosin Alpha-1 differ from Thymulin?
Thymosin Alpha-1 is a 28-amino acid peptide that enhances T-cell maturation and innate immune signalling via TLR pathways. Thymulin is a zinc-dependent nonapeptide produced in the thymus that specifically drives T-cell differentiation, declining significantly with age.
Are immune peptides suitable for long-term research protocols?
KPV and ARA-290 have been studied in chronic administration models. AICAR has primarily been used in acute metabolic research. Protocol length varies significantly by compound — consult published literature for each specific agent.
Which immune peptides are available in capsule format?
KPV (4 mg), Thymosin Alpha-1 (10 mg), and MOTS-c (10 mg) are available as capsules at Rainbow Peptide, allowing oral administration research without reconstitution.
For research use only. Not intended for human consumption. Must be 18+.